These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10981244)

  • 1. The use of ACE inhibitors as renoprotective agents in Medicaid patients with diabetes.
    Scarsi KK; Bjornson DC
    Ann Pharmacother; 2000 Sep; 34(9):1002-6. PubMed ID: 10981244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization.
    Cooke CE; Fatodu H
    J Manag Care Pharm; 2006 Oct; 12(8):649-55. PubMed ID: 17269843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
    Bian B; Kelton CM; Guo JJ; Wigle PR
    J Manag Care Pharm; 2010; 16(9):671-9. PubMed ID: 21067253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE-inhibitor use and the long-term risk of renal failure in diabetes.
    Suissa S; Hutchinson T; Brophy JM; Kezouh A
    Kidney Int; 2006 Mar; 69(5):913-9. PubMed ID: 16518351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is administration of preoperative angiotensin-converting enzyme inhibitors important for renal protection after cardiac surgery?
    Dag O; Kaygin MA; Aydin A; Limandal HK; Arslan Ü; Kiymaz A; Kahraman N; Calik ES; Erkut B
    Ren Fail; 2013; 35(5):754-60. PubMed ID: 23521631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
    Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C; Schernthaner G
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of angiotensin-converting enzyme inhibitor use in patients with type 2 diabetes in a state managed care plan.
    Timpe EM; Amarshi N; Reed PJ
    Am J Manag Care; 2004 Feb; 10(2 Pt 2):124-9. PubMed ID: 15005504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes.
    Velasquez MT; Bhathena SJ; Striffler JS; Thibault N; Scalbert E
    Metabolism; 1998 Dec; 47(12 Suppl 1):7-11. PubMed ID: 9867063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.
    Mandal AK; Markert RJ; Saklayen MG; Mankus RA; Yokokawa K
    Clin Nephrol; 1994 Sep; 42(3):170-4. PubMed ID: 7994935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
    Kiberd BA; Jindal KK
    Mayo Clin Proc; 1999 Jun; 74(6):559-64. PubMed ID: 10377929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of ACE inhibitors on diabetic patients without renal disease.
    Kirpichnikov D; Winer N; Sowers JR
    Curr Diab Rep; 2002 Feb; 2(1):21-5. PubMed ID: 12643119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.
    Swislocki AL; Siegel D
    Am J Manag Care; 2001 Mar; 7(3):283-95. PubMed ID: 11258145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.